EVANSTON, Ill.--(BUSINESS WIRE)--July 27, 2006--Northfield Laboratories Inc. (Nasdaq: NFLD - News) announced today that a preclinical study describing the use of a novel formulation of the Company's human hemoglobin-based oxygen carrier in pancreatic islet cell isolation and transplantation was presented at the World Transplantation Congress in Boston this morning.
